Rocket Pharmaceuticals (RCKT) Price & Analysis

Compare

1,619 Followers

RCKT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.19 - $22.01

Previous CloseN/A

Volume339.48K

Average Volume (3M)5.16M

Market Cap

$365.79M

Enterprise Value$25.71M

Total Cash (Recent Filing)$271.49M

Total Debt (Recent Filing)$25.20M

Price to Earnings (P/E)―

Beta1.59

Next Earnings

Nov 06, 2025

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding107,903,870

10 Day Avg. Volume9,118,679

30 Day Avg. Volume5,164,274

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.07

Enterprise Value/Revenue2.80

Enterprise Value/Gross Profit-7.73

Enterprise Value/Ebitda-0.10

Forecast

1Y Price Target

$8.82

Price Target Upside165.66% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering15

Bulls Say, Bears Say

Bulls Say

Organizational EfficiencyRocket reiterated efforts to streamline the organization with the goal of reducing operating expenses by approximately 25%.

Regulatory ApprovalThe FDA lifted the clinical hold on the pivotal Ph2 study of RP-A501 in Danon disease, which is a meaningful positive for the stock.

Trial DataThe initial pivotal dose easily cleared the efficacy bar in Ph1 data, leaving reasonable odds that this lower dose can still show approvable efficacy.

Bears Say

Clinical UncertaintyUncertainty on trial size and completion timing remains a concern for the stock.

Dose Adjustment ConcernsNew uncertainty is acknowledged given the lower dose.

Financial ConcernsThe task for RCKT management shifts to extending cash runway beyond 2Q27 to alleviate potential balance sheet overhang.

Rocket Pharmaceuticals News

Rocket Pharmaceuticals director buys $34.1K in common stock

In a regulatory filing last night, Rocket Pharmaceuticals (RCKT) disclosed that its director Elisabeth Bjork bought 10K shares...

10h ago

RCKT

Rocket Pharmaceuticals CFO Aaron Ondrey resigns to pursue other opportunities

In a regulatory filing, the company states: “On August 20, 2025, Aaron Ondrey resigned as Chief Financial Officer...

3d ago

RCKT

EMA says Rocket Pharmaceuticals withdraws MA application for Fanskya

The European Medicines Agency said that Rocket Pharmaceuticals (RCKT) B.V. withdrew its application for a marketing authorisation of...

6d ago

RCKT

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Investors looking for all of the latest earnings, mergers, and other stock market stories will find them in...

7d ago

AMD

APM

Bank of America Upgrades Rocket Pharma Stock (RCKT) After FDA Lifts Clinical Hold on Danon Disease Trial

Rocket Pharmaceuticals ($RCKT) stock rallied 29% on Wednesday as the U.S. Food and Drug Administration (FDA) lifted the...

7d ago

RCKT

BofA upgrades Rocket Pharmaceuticals to Buy after clinical hold lifted

As previously reported, BofA upgraded Rocket Pharmaceuticals (RCKT) to Buy from Neutral with a price target of $10,...

8d ago

RCKT

Rocket Pharmaceuticals upgraded to Buy from Neutral at BofA

BofA upgraded Rocket Pharmaceuticals (RCKT) to Buy from Neutral with a price target of $10, up from $4....

8d ago

RCKT

Citi says FDA may take ‘more comprehensive look’ at Sarepta Elevidys adjustment

After Rocket Pharmaceuticals (RCKT) announced that the FDA has lifted the hold on RPA501 for Danon following alignment...

8d ago

RCKT

SRPT

Target names CEO successor, Guess to go private: Morning Buzz

The major averages were trending lower near noon as investors absorb a tech-led pullback and await pivotal catalysts,...

8d ago

Rocket alignment with FDA ‘sounds reasonable,’ says Chardan

Chardan keeps a Buy rating on Rocket Pharmaceuticals (RCKT) with a $12 price target after the FDA lifted...

8d ago

RCKT

Morning Movers: Target sinks following Q2 earnings and CEO succession plan

Stock futures are slightly lower this morning as investors absorb a tech-led pullback and await pivotal catalysts, including...

8d ago

ADI

Rocket Pharmaceuticals announces clinical hold lifted on RP-A501 trial

Rocket Pharmaceuticals (RCKT) announced that the FDA has lifted the clinical hold on the company’s pivotal Phase 2...

8d ago

RCKT

Promising Outlook for Rocket Pharmaceuticals: Buy Rating Affirmed Amidst Advancements in RP-A501 Study

Analyst Yun Zhong of Wedbush maintained a Buy rating on Rocket Pharmaceuticals, retaining the price target of $16.00....

13h ago

RCKT

Hold Rating on Rocket Pharmaceuticals Amid Uncertainties in RP-A501 Study Resumption

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on RCKT stock, giving a Hold rating on...

7d ago

RCKT

RCKT FAQ

What was Rocket Pharmaceuticals’s price range in the past 12 months?

Rocket Pharmaceuticals lowest stock price was $2.19 and its highest was $22.01 in the past 12 months.

What is Rocket Pharmaceuticals’s market cap?

Rocket Pharmaceuticals’s market cap is $365.79M.

When is Rocket Pharmaceuticals’s upcoming earnings report date?

Rocket Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 70 days.

How were Rocket Pharmaceuticals’s earnings last quarter?

Rocket Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.548 by -$0.072.

Is Rocket Pharmaceuticals overvalued?

According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rocket Pharmaceuticals pay dividends?

Rocket Pharmaceuticals does not currently pay dividends.

What is Rocket Pharmaceuticals’s EPS estimate?

Rocket Pharmaceuticals’s EPS estimate is -0.48.

How many shares outstanding does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals has 107,903,870 shares outstanding.

What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?

Rocket Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.548. Following the earnings report the stock price went down -7.443%.

Which hedge fund is a major shareholder of Rocket Pharmaceuticals?

Currently, no hedge funds are holding shares in RCKT

Rocket Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-69.65%

Trailing 12-Months

Asset Growth

-5.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. (RCKT) is a clinical-stage biotechnology company focused on developing first-in-class gene therapies for rare and devastating diseases. The company operates in the pharmaceutical sector, primarily targeting inherited genetic disorders with high unmet medical needs. Rocket Pharmaceuticals leverages its proprietary lentiviral vector platform to develop gene therapies aimed at providing long-lasting and potentially curative treatments for patients.

Rocket Pharmaceuticals (RCKT) Earnings & Revenues

Historic Earnings Reports

RCKT Stock 12 Month Forecast

Average Price Target

$8.82

▲(165.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","12":"$12","23":"$23","6.5":"$6.5","17.5":"$17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.5,12,17.5,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,4.2215384615384615,5.453076923076923,6.684615384615385,7.916153846153846,9.147692307692306,10.37923076923077,11.61076923076923,12.842307692307692,14.073846153846153,15.305384615384614,16.536923076923074,17.768461538461537,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,3.4384615384615387,3.886923076923077,4.335384615384616,4.783846153846154,5.2323076923076925,5.680769230769231,6.1292307692307695,6.577692307692308,7.026153846153846,7.474615384615385,7.923076923076923,8.371538461538462,{"y":8.82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,2.913846153846154,2.8376923076923077,2.7615384615384615,2.6853846153846157,2.6092307692307695,2.5330769230769232,2.456923076923077,2.3807692307692307,2.304615384615385,2.2284615384615387,2.1523076923076925,2.0761538461538462,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.23,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >